We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ONO-7475 in Patients With Acute Leukemias

This study is currently recruiting participants.
Verified October 2017 by Ono Pharmaceutical Co. Ltd
Sponsor:
ClinicalTrials.gov Identifier:
NCT03176277
First Posted: June 5, 2017
Last Update Posted: October 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Ono Pharmaceutical Co. Ltd
  Purpose
This study will determine the safety and maximum tolerated dose of ONO-7475 in patients with relapsed or refractory acute leukemia and evaluate the efficacy of ONO-7475 in patients with newly diagnosed AML

Condition Intervention Phase
Acute Leukemia Drug: ONO-7475 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias

Resource links provided by NLM:


Further study details as provided by Ono Pharmaceutical Co. Ltd:

Primary Outcome Measures:
  • Incidence, nature, and severity of (serious) Adverse Events [ Time Frame: Up to 12 months ]
    To determine the safety and tolerability of ONO-7475

  • Clinically significant changes in electroretinogram (ERG) [ Time Frame: Up to 12 months ]
    To determine the safety and tolerability of ONO-7475

  • Clinically significant ophthalmology examinations [ Time Frame: Up to 12 months ]
    To determine the safety and tolerability of ONO-7475

  • Clinically significant electrocardiogram (ECG) [ Time Frame: Up to 12 months ]
    To determine the safety and tolerability of ONO-7475


Secondary Outcome Measures:
  • Determination of Maximum Tolerated Dose (MTD) [ Time Frame: Up to 12 months ]
    As assessed by the incidence, nature, and severity of (serious) Adverse Events

  • Determination of recommended pharmacological dose [ Time Frame: Up to 12 months ]
    As assessed by the Plasma inhibitory activity (PIA)

  • Pharmacokinetics (Tmax) [ Time Frame: Day 1 and Day 28 of Cycle 1 ]
    Assessment of the time to reach maximum observed plasma concentration of ONO-7475.

  • Pharmacokinetics (Cmax) [ Time Frame: Day 1 and Day 28 of Cycle 1 ]
    Assessment of the maximum plasma concentration of ONO-7475.

  • Pharmacokinetics (AUC) [ Time Frame: Day 1 and Day 28 of Cycle 1 ]
    Assessment of the plasma area under the curve (day 1 and 28) of ONO-7475.

  • Pharmacokinetics (T1/2) [ Time Frame: Day 1 and Day 28 of Cycle 1 ]
    Assessment of the plasma decay half life of ONO-7475.

  • Pharmacokinetics (Ctrough) [ Time Frame: Cycle 1 predose Day 7 and Day 15 ]
    Assessment of the trough concentration of ONO-7475 in the plasma.

  • Pharmacokinetics (Cmax) - Food effect [ Time Frame: Day 57 (Cycle 3 Day 1) ]
    Assessment of the food effect on the maximum plasma concentration of ONO-7475.

  • Pharmacokinetics (Tmax) - - Food effect [ Time Frame: Day 57 (Cycle 3 Day 1) ]
    Assessment of the food effect on the time to reach maximum observed plasma concentration of ONO-7475.

  • Pharmacokinetics (AUC) - Food effect [ Time Frame: Day 57 (Cycle 3 Day 1) ]
    Assessment of the food effect on the plasma area under the curve of ONO-7475

  • Pharmacokinetics (T1/2) - Food effect [ Time Frame: Day 57 (Cycle 3 Day 1) ]
    Assessment of the food effect on the plasma decay half life of ONO-7475.

  • Pharmacokinetics (Ctrough) - Food effect [ Time Frame: Day 57 (Cycle 3 Day 1) ]
    Assessment of the food effect on the trough concentration of ONO-7475 in the plasma.

  • Pharmacodynamics of ONO-7475 [ Time Frame: Up to 12 months ]
    Assessment of the pharmacodynamic activity of ONO-7475 as assessed by a PIA assay (pAxl/pMer inhibition).

  • Overall response rate (ORR) [ Time Frame: Up to 12 months ]
    CR + CRi + PR

  • Duration of response (DOR) [ Time Frame: Up to 12 months ]
    Duration in months from PR, CRi and CR

  • Progression free survival (PFS) [ Time Frame: Up to 12 months ]
    Duration in months from first study treatment to disease progression or death

  • Relapse free survival [ Time Frame: Up to 12 months ]
    Time of disease relapse or patient death from any cause

  • Event-free survival [ Time Frame: Up to 12 months ]
    Time of treatment failure, disease relapse or patient death from any cause

  • Remission duration [ Time Frame: Up to 12 months ]
    Disease relapse (measured at CR)

  • Minimal residual disease (MRD) [ Time Frame: Up to 12 months ]
    Assessed by flow cytometry for patients who achieve CR


Estimated Enrollment: 42
Actual Study Start Date: June 26, 2017
Estimated Study Completion Date: November 10, 2019
Estimated Primary Completion Date: May 10, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ONO-7475: dose escalation
Successive dose escalation cohorts to determine MTD
Drug: ONO-7475
ONO-7475 tablets

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients aged ≥18 years at time of screening
  2. Written informed consent by the patient (or legal representative) prior to admission to this study. In addition any locally required authorization (Health Insurance Portability and Accountability Act in the USA [HIPAA], obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.
  3. Adequate renal and hepatic function defined as:

    • Total bilirubin within 1.5 x ULN, except those with Gilberts syndrome for whom this must be <3 x ULN
    • AST(SGOT) and ALT(SGPT) <2.5 x ULN
    • Calculated Creatinine clearance>/= 45ml/min
    • Serum Albumin >3g/dL
  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  5. Life expectancy of at least 3 months
  6. Sexually active female patients of childbearing potential and sexually active male patients must agree to use an effective method of birth control (e.g., barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices) during the entire duration of the study and for 4 months after final administration of study drug. Note that sterility in female patients must be confirmed in the patients' medical records and be defined as any of the following: surgical hysterectomy with bilateral oophorectomy, bilateral tubular ligation, natural menopause with last menses >1 year ago; radiation induced oophorectomy with last menses >1 year ago; chemotherapy induced menopause with last menses >1 year ago.
  7. Male patients must use a condom from the time of the first administration of ONO-7475 until 4 months following administration of the last dose.

8. Diagnosis of AML according to WHO criteria 2016.

9. Relapsed or refractory AML patients with at least 5% blasts by bone marrow biopsy or aspirate, or at least 1% blasts in peripheral blood, not likely to benefit from standard salvage chemotherapy.

10. All patients must have received at least one prior therapy - 1 cycle of cytarabine containing regimen or 2 cycles of hypomethylating agent - before determination of refractory status (defined as response duration less than 3 months or no response)

Exclusion Criteria:

  1. Primary disease involving the Central Nervous System (CNS)
  2. QTcF prolongation defined as a QTcF interval >470 msec or other significant ECG abnormalities including 2nd degree (type II) or 3rd degree AV block or bradycardia (ventricular rate <50 beats/min).
  3. Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  4. HIV/active Hepatitis B infection
  5. Clinically significant (as defined by screening ophthalmologist, central reading center, and sponsor) ERG reading, retinal disease (e.g. retinitis pigmentosa including Mertk mutations), retinal hemorrhage or any disorder which affects ERG, and may inhibit follow up for retinal toxicity
  6. Serious intercurrent medical or psychiatric illness that will prevent participation or compliance with study procedures, including serious active infection
  7. Acute promyelocytic leukemia (FAB M3 classification)
  8. Patients must be recovered to Grade 1 or stabilized from the effects (excluding alopecia) of any prior therapy for their malignancies
  9. Concurrent treatment with other investigational drugs.
  10. Daily requirement for corticosteroids ≥ prednisone 10 mg/day or equivalent.
  11. Prior hematopoietic stem cell transplantation within 12 weeks of the first dose of study treatment or ongoing immunosuppressive therapy for graft versus host disease
  12. Participation in another clinical trial with any investigational drug within 30 days prior to study entry.
  13. No prior AML therapy (non-experimental) within 28 days of first dose of ONO-7475
  14. No prior radiotherapy within 21 days of screening. Localized radiation therapy to a single site within the last 7 days is acceptable. Concurrent radiotherapy is not permitted.
  15. Patients undergoing current treatments for other cancers
  16. Pregnant or lactating women
  17. Proliferative disease (WBC > 30 x 109 /L) (confirmed at time of study entry prior to first dose)
  18. Diagnosed or treated for a malignancy other than AML within 5 years, or who were previously diagnosed with a malignancy other than AML and have any radiographic or biochemical marker evidence of malignancy. Note: Patients with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy at any time are not excluded
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03176277


Contacts
Contact: ONO Pharma UK Ltd +44 (0)2074214920 ctinfo@ono-uk.co.uk

Locations
United States, Kansas
University of Kansas Cancer Center Not yet recruiting
Fairway, Kansas, United States, 66205
Principal Investigator: Tara Lin, MD         
United States, Michigan
University of Michigan Not yet recruiting
Ann Arbor, Michigan, United States, 48109
Principal Investigator: Dale Bixby, MD         
United States, New York
Roswell Park Cancer Institute Not yet recruiting
Buffalo, New York, United States, 14263
Principal Investigator: Eunice Wang, MD         
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Principal Investigator: Margaret Kasner, MD         
United States, South Carolina
Medical University of South Carolina - Hollins Cancer Center Recruiting
Charleston, South Carolina, United States, 29425
Principal Investigator: Juan Carlos Varela, MD         
Sponsors and Collaborators
Ono Pharmaceutical Co. Ltd
Investigators
Study Director: ONO Pharma UK Ltd Drug Development Division
  More Information

Responsible Party: Ono Pharmaceutical Co. Ltd
ClinicalTrials.gov Identifier: NCT03176277     History of Changes
Other Study ID Numbers: ONO-7475-01
First Submitted: May 19, 2017
First Posted: June 5, 2017
Last Update Posted: October 11, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ono Pharmaceutical Co. Ltd:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
MER
MERTK
TYRO3
AXL
AML
de novo AML
Relapsed/ Refractory AML
TAM

Additional relevant MeSH terms:
Leukemia
Acute Disease
Neoplasms by Histologic Type
Neoplasms
Disease Attributes
Pathologic Processes